Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Arno Therapeutics

This article was originally published in Start Up

Executive Summary

In addition to camptothecins and HDAC inhibitors, Arno Therapeutics Inc.'s pipeline of cancer candidates includes a Phase I agent that targets the PI3K/Akt pathway. Arno thinks it's potentially a first-in-class compound that could have broad activity against a range of solid and liquid tumors. Furthermore, preclinical data show synergy with approved targeted agents.
Advertisement

Related Content

Deals Of The Week Ponders The ACA
Paloma Pharmaceuticals Inc.
Intellikine Inc.
It's Apples Versus Oranges in the PI3 Kinase Race
Start-Up Previews (10/2009)
Start-Up Previews (10/2009)
It's Apples Versus Oranges in the PI3 Kinase Race

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC091856

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel